Table 2 Characteristics of subjective cognitive decline (SCD) and dementia due to Alzheimer’s disease (AD) subjects in both cohorts. The count (n), mean or median with percentage (%), standard deviation (SD) or interquartile range (IQR) are shown for each variable. MMSE Mini-Mental State Exam, CNS central nervous system, MTA Medial Temporal Atrophy score, Aβ 1–42 amyloid beta 1–42, t-tau total tau, p-tau phosphorylated tau

Female (n, %)

76 (39%)

104 (49%)

89 (44%)

94 (48%)

Age (mean, SD)

62 ± 8

67 ± 8^a

60 ± 10

69 ± 10^a

MMSE (median, IQR)

28 (27–29)

21 (17–24)^a

29 (28–30)^b

22 (18–25)^a,b

Vascular disease (n, %)

34 (17%)

40 (19%)

35 (17%)

32 (16%)

CNS disease (n, %)

20 (10%)

14 (7%)

22 (11%)

19 (10%)

Psychiatric disease (n, %)

6 (3%)

8 (4%)

5 (2%)

1 (1%)

Antidepressants (n, %)

20 (10%)

26 (12%)

16 (8%)

19 (10%)

Benzodiazepines (n, %)

11 (6%)

12 (6%)

18 (9%)

15 (8%)

Anti-epileptic drugs (n, %)

4 (2%)

3 (1%)

4 (2%)

3 (2%)

Acetylcholinesterase inhibitors (n, %)

0 (0%)

16 (7%)^a

1 (0%)

18 (9%)^a

MRI

n = 176

n = 199

n = 175

n = 156

 MTA (median, IQR)

0 (0–0.5)

1 (0.5–2)^a

0 (0–0.5)

1.5 (1–2.5)^a,b

 Fazekas (median, IQR)

1 (0–1)

1 (0–1)

0 (0–1)

1 (0.5–1)^a

Cerebrospinal fluid

n = 183

n = 169

n = 120

n = 141

 Aβ 1–42 (mean, SD)

1031 ± 268

663 ± 136^a

1090 ± 197

694 ± 162^a

 t-tau (mean, SD)

302 ± 214

731 ± 413^a

267 ± 119

610 ± 321^a,b

 p-tau (mean, SD)

50 ± 23

89 ± 35^a

47 ± 16

85 ± 38^a

Amyloid-PET

n = 32

n = 34

n = 11

n = 17

 Positive PET (n, %)

12 (38%)

34 (100%)^a

3 (27%)

14 (82%)^a